[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003002593A3 - Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv - Google Patents

Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv Download PDF

Info

Publication number
WO2003002593A3
WO2003002593A3 PCT/EP2002/007128 EP0207128W WO03002593A3 WO 2003002593 A3 WO2003002593 A3 WO 2003002593A3 EP 0207128 W EP0207128 W EP 0207128W WO 03002593 A3 WO03002593 A3 WO 03002593A3
Authority
WO
WIPO (PCT)
Prior art keywords
dipeptidyl peptidase
catalysis
peptide structures
structures useful
modulation
Prior art date
Application number
PCT/EP2002/007128
Other languages
English (en)
Other versions
WO2003002593A2 (fr
Inventor
Hans Ulrich Demuth
Torsten Hoffmann
Susanne Manhart
Matthias Hoffmann
Jochen Heins
Original Assignee
Probiodrug Ag
Hans Ulrich Demuth
Torsten Hoffmann
Susanne Manhart
Matthias Hoffmann
Jochen Heins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag, Hans Ulrich Demuth, Torsten Hoffmann, Susanne Manhart, Matthias Hoffmann, Jochen Heins filed Critical Probiodrug Ag
Priority to JP2003508973A priority Critical patent/JP2004530729A/ja
Priority to EP02762308A priority patent/EP1399469A2/fr
Priority to CA002419888A priority patent/CA2419888A1/fr
Publication of WO2003002593A2 publication Critical patent/WO2003002593A2/fr
Priority to NO20030900A priority patent/NO20030900L/no
Publication of WO2003002593A3 publication Critical patent/WO2003002593A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I), et ses sels acceptables sur le plan pharmaceutique. On peut utiliser ces composés afin de préparer un médicament prophylactique ou thérapeutique pour un état dans lequel la modulation de l'activité de dipeptidyle peptidase IV joue un rôle intermédiaire, cet état étant, de préférence, sélectionné dans la diminution de la tolérance au glucose, le diabète sucré, la glycosurie ou l'acidose métabolique.
PCT/EP2002/007128 2001-06-27 2002-06-27 Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv WO2003002593A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003508973A JP2004530729A (ja) 2001-06-27 2002-06-27 ジペプチジルペプチダーゼiv触媒作用の拮抗調節に有用なペプチド構造
EP02762308A EP1399469A2 (fr) 2001-06-27 2002-06-27 Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
CA002419888A CA2419888A1 (fr) 2001-06-27 2002-06-27 Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
NO20030900A NO20030900L (no) 2001-06-27 2003-02-26 Peptidstrukturer nyttige for kompetitiv modulering av dipeptidyl peptidaseIV-katalyse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01114796.4 2001-06-27
EP01114796 2001-06-27

Publications (2)

Publication Number Publication Date
WO2003002593A2 WO2003002593A2 (fr) 2003-01-09
WO2003002593A3 true WO2003002593A3 (fr) 2003-09-04

Family

ID=8177756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007128 WO2003002593A2 (fr) 2001-06-27 2002-06-27 Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv

Country Status (8)

Country Link
EP (1) EP1399469A2 (fr)
JP (1) JP2004530729A (fr)
CN (2) CN1688599A (fr)
CA (1) CA2419888A1 (fr)
NO (1) NO20030900L (fr)
RU (2) RU2299066C2 (fr)
WO (1) WO2003002593A2 (fr)
ZA (3) ZA200301312B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211555A1 (de) * 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1608317B1 (fr) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
EP1620082B9 (fr) 2003-05-05 2010-08-25 Probiodrug AG Utilisation d'effecteurs de glutaminyl- et de glutamate-cyclases pour traiter la maladie d'alzheimer et le syndrome de down
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (fr) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Inhibiteurs de la dipeptidylpeptidase
NZ546322A (en) 2003-10-15 2008-11-28 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
EP2338490A3 (fr) 2003-11-03 2012-06-06 Probiodrug AG Combinaisons utiles pour le traitement de désordres neuronales
KR20120126133A (ko) 2003-11-17 2012-11-20 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
BR122018014389B1 (pt) 2004-01-20 2023-04-25 Novartis Ag Processo para preparar comprimido farmacêutico por compressão direta
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN1938286A (zh) 2004-03-29 2007-03-28 默克公司 作为11-β-羟甾类脱氢酶-1抑制剂的二芳基三唑
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
CA2574418A1 (fr) 2004-07-23 2006-02-02 Susan Marie Royalty Inhibiteurs de peptidase
EP1797034B1 (fr) 2004-08-06 2010-06-30 Merck Sharp & Dohme Corp. Composes de sulfonyle comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1
EP1828192B1 (fr) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
JP5068174B2 (ja) 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー.ブイ. Dpp−ivを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP5154927B2 (ja) 2005-05-30 2013-02-27 Msd株式会社 新規ピペリジン誘導体
JP2011201923A (ja) * 2005-07-01 2011-10-13 Snow Brand Milk Products Co Ltd ジペプチジルペプチダーゼiv阻害剤
CA2619770A1 (fr) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Derive phenylpyridone
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
RU2008116844A (ru) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
CA2627139A1 (fr) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Nouveau derive de benzoxathiine
CA2629018C (fr) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Derive spiro aza-substitue
EP1971614A1 (fr) 2005-11-14 2008-09-24 Probiodrug AG Derives de pyrrolidine a fusion de cyclopropyle, en tant qu'inhibiteurs de dipeptidyle peptidase iv (dp iv)
WO2007064208A1 (fr) 2005-11-30 2007-06-07 Campina Nederland Holding B.V. Utilisation d'un hydrolysat de proteine pour stimuler l'activite de peptide 1 similaire au glucagon
EP1801098A1 (fr) 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
EP2072519A4 (fr) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Dérivé de diarylcétimine
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP1935420A1 (fr) 2006-12-21 2008-06-25 Merck Sante Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1
EP2145884B1 (fr) 2007-04-02 2014-08-06 Msd K.K. Dérivé d'indoledione
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2008137105A1 (fr) 2007-05-07 2008-11-13 Merck & Co., Inc. Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2998314B1 (fr) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
WO2009110510A1 (fr) 2008-03-06 2009-09-11 萬有製薬株式会社 Dérivé d'alkylaminopyridine
CA2717384A1 (fr) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Derive de diarylmethylamide a activite antagoniste sur un recepteur d'hormone concentrant la melanine
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2358200A4 (fr) 2008-11-17 2012-05-16 Merck Sharp & Dohme Amines bicycliques substituées pour le traitement du diabète
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
CN102791701B (zh) 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
EP2538784B1 (fr) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Dérivés de benzimidazole utiles comme agents antidiabétiques
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
CA2795513A1 (fr) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulateurs du recepteur de gpr119 et traitement de troubles associes
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN106831980B (zh) * 2011-11-04 2020-09-15 株式会社日皮 Dpp-4抑制剂
CN104159912B (zh) * 2012-03-09 2016-11-09 森永乳业株式会社 二肽基肽酶iv 抑制剂
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
CA2898482A1 (fr) 2013-02-22 2014-08-28 Linda L. Brockunier Composes bicycliques antidiabetiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
AU2014323008B2 (en) 2013-09-23 2018-02-08 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
MX2017011586A (es) 2015-03-09 2017-10-26 Intekrin Therapeutics Inc Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
CN105362272A (zh) * 2015-12-14 2016-03-02 上海壹志医药科技有限公司 罗通定的药物用途
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (fr) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020104456A1 (fr) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
EP3924058A1 (fr) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
CN116249697A (zh) 2020-08-18 2023-06-09 默沙东有限责任公司 二环庚烷吡咯烷食欲素受体激动剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"BACHEM Catalogue Peptides and Biochemicals Germany", 1999, BACHEM BIOCHEMICA GMBH, HEIDELBERG, DE, XP002218295 *
"SIGMA Catalogue Biochemicalien, Diagnostica en Benodigheden voor Life Science Research", 1997, SIGMA CHEMICAL COMPANY, SIGMA-ALDRICH BV, ZWIJNDRECHT, NL, XP002218294 *
AUGUSTYNS K ET AL: "THE UNIQUE PROPERTIES OF DIPEPTIDYL-PEPTIDASE IV (DPP IV/CD26) AND THE THERAPEUTIC POTENTIAL OF DPP IV INHIBITORS", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 4, 1999, pages 311 - 327, XP000870290, ISSN: 0929-8673 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
ZA200301312B (en) 2004-03-30
CN1688599A (zh) 2005-10-26
NO20030900L (no) 2003-04-24
JP2004530729A (ja) 2004-10-07
RU2299066C2 (ru) 2007-05-20
CA2419888A1 (fr) 2003-01-09
EP1399469A2 (fr) 2004-03-24
NO20030900D0 (no) 2003-02-26
ZA200300595B (en) 2004-02-13
CN1471538A (zh) 2004-01-28
WO2003002593A2 (fr) 2003-01-09
RU2003105463A (ru) 2004-11-27
ZA200300833B (en) 2004-02-10

Similar Documents

Publication Publication Date Title
WO2003002593A3 (fr) Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
EP1400529A4 (fr) Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci
WO2001082916A3 (fr) Compositions therapeutiques combinees et leurs methodes d'utilisation
WO2004037181A3 (fr) Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
EP1803721A4 (fr) Dérivé novateur de glucitol, précurseur de ce médicament et sel de celui-ci, ainsi qu'un agent thérapeutique pour diabètes contenant celui-ci
WO2003044015A3 (fr) Acides heteroarylalkanoiques substitues
CA2474578A1 (fr) Nouveaux derives de pyridine et de pyrimidine
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
WO2005044192A3 (fr) Composes triazole et utilisations associees
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
IN2015DN01132A (fr)
WO2001096295A3 (fr) Composes organiques
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2004037789A3 (fr) Derives de methylene uree
UA83057C2 (ru) Замещенные производные диоксида тиазолбензоизотиазола и их применение
WO2002030867A3 (fr) Medicaments destines au diabete
WO2002042271A3 (fr) Biphenylcarboxamides utiles comme hypolipidemiants
WO1999049854A3 (fr) Utilisation de dexmedetomidine pour la sedation dans une unite de soins intensifs
WO2001000566A3 (fr) Acides phenoxyacetiques substitues
PT1408966E (pt) Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes
WO2002000166A3 (fr) Nouveaux composes utiles comme agents antibacteriens
NO20055971L (no) Cyanofluorpyrrolidinderivat
WO2003022280A3 (fr) 3-glyoxlylamide-indoles pour traitement du cancer
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2419888

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/01312

Country of ref document: ZA

Ref document number: 200301312

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002762308

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002328305

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 028022467

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003508973

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002762308

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642